Skip to main content

NeuroStar® Advanced Therapy Launches New “Tap Into a New Possibility” Campaign for Depression Awareness

Written by Customer Service on . Posted in Public Companies.

Company invests $14.5 million to expand education for patients and physicians about NeuroStar® Advanced Therapy

MALVERN, Pa., March 03, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the launch of their new campaign to increase awareness of the impact of depression on millions of people. The campaign is called “Tap into a New Possibility” and illustrates how overwhelmed patients with major depressive disorder (MDD) feel about managing their condition, especially if they have not benefited from multiple treatment attempts.   

“Too many people are suffering, and traditional treatments don’t work for everyone. It’s critical that patients and their physicians are aware of all of the treatment options available to them, especially if they haven’t found the one that works for them yet,” stated Claire Sears, Vice President of Marketing at Neuronetics, Inc. “Our marketing spend this year demonstrates our commitment to investing in the category and making sure patients know about NeuroStar Advanced Therapy – a safe, effective, non-drug treatment for MDD.”

The omnichannel campaign will launch on March 3rd and will be extended across owned channels and established health platforms, with a goal of reaching and educating more people who are seeking information about depression treatments and NeuroStar.

For more information about NeuroStar, please visit neurostar.com

About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience and the largest TMS company in the industry, Neuronetics is redefining patient and physician expectations by designing and developing products that improve the quality of life for people suffering from psychiatric disorders. An FDA-cleared, non-drug, noninvasive treatment for people with depression, Neuronetics’ NeuroStar® Advanced Therapy system is today’s leading transcranial magnetic stimulation (TMS) treatment for major depressive disorder with over 4.3 million treatments delivered. NeuroStar is widely researched and backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety information and indications for use, visit NeuroStar.com.

Media Contact:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.